Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strickler

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to ComeChristopher Chen, Maria Di Bartolomeo, Salvatore Corallo, et al.
Annals of Surgical Oncology|June 20, 2020
Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine CarcinomaRobin Schmitz, Rui Mao, Dimitrios Moris, et al.
JAMA Oncology|March 3, 2022
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A ReviewJohn H Strickler, Takayuki Yoshino, Rondell P Graham, et al.
Frontiers in Oncology|September 14, 2018
Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal CancerJingquan Jia, Michael A Morse, Rebecca J Nagy, et al.
NPJ Precision Oncology|April 3, 2026
Profiling KRAS mutations in whole blood by error-corrected maximum depth sequencingRyne C Ramaker, Yuchen Zhang, John H Strickler, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumoursMasaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, et al.
Archives of Pathology & Laboratory Medicine|March 1, 2014
Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplicationDaniel P Nussbaum, Syamal D Bhattacharya, Xiaoyin Jiang, et al.
Journal of Medical Economics|August 10, 2018
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the USChristopher N Graham, Alexandra Christodoulopoulou, Hediyyih N Knox, et al.
The Oncologist|July 11, 2023
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature ReviewJohn H Strickler, Takayuki Yoshino, Kendall Stevinson, et al.
JCO Oncology Practice|November 14, 2025
Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal AdenocarcinomaEthan S Agritelley, Ryne C Ramaker, Matthew Bao, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to ComeChristopher Chen, Maria Di Bartolomeo, Salvatore Corallo, et al.
Annals of Surgical Oncology|June 20, 2020
Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine CarcinomaRobin Schmitz, Rui Mao, Dimitrios Moris, et al.
JAMA Oncology|March 3, 2022
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A ReviewJohn H Strickler, Takayuki Yoshino, Rondell P Graham, et al.
Frontiers in Oncology|September 14, 2018
Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal CancerJingquan Jia, Michael A Morse, Rebecca J Nagy, et al.
NPJ Precision Oncology|April 3, 2026
Profiling KRAS mutations in whole blood by error-corrected maximum depth sequencingRyne C Ramaker, Yuchen Zhang, John H Strickler, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumoursMasaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, et al.
Archives of Pathology & Laboratory Medicine|March 1, 2014
Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplicationDaniel P Nussbaum, Syamal D Bhattacharya, Xiaoyin Jiang, et al.
Journal of Medical Economics|August 10, 2018
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the USChristopher N Graham, Alexandra Christodoulopoulou, Hediyyih N Knox, et al.
The Oncologist|July 11, 2023
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature ReviewJohn H Strickler, Takayuki Yoshino, Kendall Stevinson, et al.
JCO Oncology Practice|November 14, 2025
Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal AdenocarcinomaEthan S Agritelley, Ryne C Ramaker, Matthew Bao, et al.
Pageof 10